Penumbra (PEN) Stock Price, News & Analysis

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PEN shares.
View PEN analyst ratings or view top-rated stocks.

9 brokerages have issued twelve-month target prices for Penumbra's shares. Their PEN share price targets range from $240.00 to $376.00. On average, they expect the company's stock price to reach $304.45 in the next year. This suggests a possible upside of 50.7% from the stock's current price.
View analysts price targets for PEN or view top-rated stocks among Wall Street analysts.

Penumbra's stock was trading at $251.54 at the start of the year. Since then, PEN stock has decreased by 19.7% and is now trading at $201.98.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our PEN earnings forecast.

Penumbra will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Penumbra, Inc. (NYSE:PEN) issued its earnings results on Thursday, February, 22nd. The company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.71 by $0.05. The firm earned $284.68 million during the quarter, compared to analysts' expectations of $286.62 million. Penumbra had a trailing twelve-month return on equity of 7.49% and a net margin of 8.59%. Penumbra's quarterly revenue was up 28.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.16 EPS.

ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Indxx Medical Devices ETF (MDEV), MFAM Small-Cap Growth ETF (MFMS), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and ProShares Metaverse ETF (VERS).

Penumbra updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

Penumbra's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.49%), Congress Asset Management Co. MA (0.07%), Diversified Trust Co (0.02%), Artemis Investment Management LLP (0.00%) and Mather Group LLC. (0.00%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends.

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.